JP2024507540A5 - - Google Patents

Info

Publication number
JP2024507540A5
JP2024507540A5 JP2023550601A JP2023550601A JP2024507540A5 JP 2024507540 A5 JP2024507540 A5 JP 2024507540A5 JP 2023550601 A JP2023550601 A JP 2023550601A JP 2023550601 A JP2023550601 A JP 2023550601A JP 2024507540 A5 JP2024507540 A5 JP 2024507540A5
Authority
JP
Japan
Prior art keywords
seq
car
sequence
heavy chain
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023550601A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024507540A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/018029 external-priority patent/WO2022183074A2/en
Publication of JP2024507540A publication Critical patent/JP2024507540A/ja
Publication of JP2024507540A5 publication Critical patent/JP2024507540A5/ja
Pending legal-status Critical Current

Links

JP2023550601A 2021-02-25 2022-02-25 抗psma抗体及びcar-t構造 Pending JP2024507540A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163153884P 2021-02-25 2021-02-25
US63/153,884 2021-02-25
PCT/US2022/018029 WO2022183074A2 (en) 2021-02-25 2022-02-25 Anti-psma antibodies and car-t structures

Publications (2)

Publication Number Publication Date
JP2024507540A JP2024507540A (ja) 2024-02-20
JP2024507540A5 true JP2024507540A5 (cg-RX-API-DMAC7.html) 2025-03-04

Family

ID=80819665

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023550601A Pending JP2024507540A (ja) 2021-02-25 2022-02-25 抗psma抗体及びcar-t構造

Country Status (9)

Country Link
US (1) US20240226162A9 (cg-RX-API-DMAC7.html)
EP (1) EP4298130A2 (cg-RX-API-DMAC7.html)
JP (1) JP2024507540A (cg-RX-API-DMAC7.html)
KR (1) KR20230148828A (cg-RX-API-DMAC7.html)
CN (1) CN117500835A (cg-RX-API-DMAC7.html)
AU (1) AU2022226277A1 (cg-RX-API-DMAC7.html)
CA (1) CA3211138A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023009874A (cg-RX-API-DMAC7.html)
WO (1) WO2022183074A2 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109862784A (zh) 2016-08-24 2019-06-07 特尼奥生物股份有限公司 产生经修饰的仅有重链的抗体的转基因非人动物
EP3559035A1 (en) 2016-12-21 2019-10-30 TeneoBio, Inc. Anti-bcma heavy chain-only antibodies
EA202091557A1 (ru) 2017-12-22 2020-11-18 Тенеобио, Инк. Антитела, содержащие только тяжелые цепи, которые связываются с cd22
CA3133654A1 (en) 2019-04-05 2020-10-08 Teneobio, Inc. Heavy chain antibodies binding to psma
CN114206927B (zh) 2019-06-14 2025-03-21 特尼奥生物股份有限公司 与cd22和cd3结合的多特异性重链抗体
TW202442689A (zh) 2023-03-03 2024-11-01 美商亞森諾生物科學公司 靶向psma及ca9之系統
WO2025183244A1 (ko) * 2024-02-29 2025-09-04 주식회사 피비앱셀 Psma에 대한 항체 및 그의 용도
WO2026107088A1 (en) * 2024-11-13 2026-05-21 Poseida Therapeutics, Inc. Dual car constructs and methods of use

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
MXPA05004677A (es) 2002-10-31 2005-11-17 Genentech Inc Metodos y composiciones para aumentar la produccion de anticuerpos.
WO2004065417A2 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
EP1776383B1 (en) 2004-07-22 2014-08-20 Erasmus University Medical Center Rotterdam Binding molecules
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
CN102421801B (zh) 2009-03-10 2016-03-16 比奥根Ma公司 抗-bcma抗体
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
JP2019506155A (ja) * 2016-01-12 2019-03-07 クレッシェンド、バイオロジックス、リミテッドCrescendo Biologics Limited 治療分子
IL299221A (en) 2016-06-21 2023-02-01 Teneobio Inc Cd3 binding antibodies
CN109862784A (zh) 2016-08-24 2019-06-07 特尼奥生物股份有限公司 产生经修饰的仅有重链的抗体的转基因非人动物
CR20220578A (es) 2016-09-14 2023-01-17 Teneobio Inc Anticuerpos de unión a cd3
AU2019274654B2 (en) * 2018-05-23 2023-07-20 Pfizer Inc. Antibodies specific for CD3 and uses thereof
CA3133654A1 (en) * 2019-04-05 2020-10-08 Teneobio, Inc. Heavy chain antibodies binding to psma

Similar Documents

Publication Publication Date Title
JP2021530236A5 (cg-RX-API-DMAC7.html)
KR102710963B1 (ko) 항b7-h3의 모노클로널 항체 및 그가 세포 치료 중에서의 응용
JP2022505445A5 (cg-RX-API-DMAC7.html)
US10047163B2 (en) Multispecific constructs
JP2022537931A5 (cg-RX-API-DMAC7.html)
JP2022526595A5 (cg-RX-API-DMAC7.html)
CN110396129B (zh) 人源化cd19抗原结合单链抗体及其嵌合抗原受体、免疫细胞和应用
JP2024508808A5 (cg-RX-API-DMAC7.html)
JP2018502050A5 (cg-RX-API-DMAC7.html)
BR112020004543A2 (pt) proteínas de ligação ativadas condicionalmente restritas
JP2022512043A (ja) 合理的に設計された新規なタンパク質組成物
TW202302631A (zh) 可誘導性結合蛋白和使用方法
JP2014510084A (ja) 二重特異性および単一特異性の非対称な抗体ならびにそれらの作製方法
CN118063619A (zh) 工程化的异源二聚体蛋白质
CN103687879A (zh) 多价抗原结合fv分子
JP2020530777A (ja) 多重特異性抗体とその作製及び使用方法
US20240092899A1 (en) Bispecific antibody
KR20210107747A (ko) 항체 융합 단백질, 이의 제조 방법 및 이의 적용
JP2020536512A (ja) タンパク性ヘテロ二量体及びその使用
JP2024507693A5 (cg-RX-API-DMAC7.html)
JP2026510999A (ja) Cd19/cd38多重特異性抗体
TWI906795B (zh) 特異性結合Claudin 18.2的抗體及其製法和應用
WO2024165049A1 (zh) 抗cdh6的抗体及其用途
CN119137147A (zh) 具有增加的选择性的多链多靶向性双特异性抗原结合分子
CN104105706A (zh) 用于治疗疾病的抗人sema4A抗体